Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a **combination dietary supplement** consisting of **red yeast rice** and **omega-3 polyunsaturated fatty acids (PUFAs)**, commonly formulated as fish oil. Red yeast rice provides monacolins, naturally occurring compounds that inhibit HMG-CoA reductase, the same target as statins, leading to reduced cholesterol synthesis in the liver. Omega-3 PUFAs, primarily EPA and DHA, exert anti-inflammatory effects and help lower triglyceride levels. In clinical trials, the combination has been shown to **improve lipid profiles** (lowering LDL-C, total cholesterol, apoB, and hsCRP) and endothelial function in subjects with mild hypercholesterolemia. Supplements may include other active ingredients such as coenzyme Q10, astaxanthin, folic acid, and vitamin B6, but the critical active components are red yeast rice (monacolins) and omega-3 PUFAs (EPA, DHA)[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on red yeast rice + omega-3.